
CLAIMS

1. Ophthalmologic preparation containing hyaluronic acid, **characterized in that,** it is in a form of a solid fibrous carrier that comprises water soluble nano-fibers containing hyaluronic acid or a pharmaceutically acceptable salt thereof,

and/or at least one derivative of hyaluronic acid of a general formula I



(I),

wherein R^+ is H^+ or pharmaceutically acceptable salt,

R^1 is H or $–C(=O)C_xH_y$ or furanyl, where x is integer in the range 3 to 21 and y is integer in the range 7 to 43 and C_xH_y is linear or branched, saturated or unsaturated chain C_3-C_{21}, one or more R^1-$C(=O)C_xH_y$ or furanyl being at least in one repeating unit and where n is in the range 12 to 4 000,

and at least one a water soluble synthetic polymer selected from the group containing polyethylene oxide or polyvinyl alcohol,

and at least one active agent is contained in the whole capacity of nano-fibers.

2. Ophthalmologic preparation according to claim 1, **characterized in that,** the derivative of hyaluronic acid is selected from the group containing palmitoyl hyaluronan, caproyl hyaluronan, oleyl hyaluronan, butanoyl hyaluronan, linoleoyl hyaluronan or furanyl hyaluronan.

3. Ophthalmologic preparation according to claim 1 or 2, **characterized in that,** the active agent is selected from the group containing anti-allergic, antibiotic, antimycotic, antineoplastic, anti-inflammatory, antiviral, antiglaucoma, antiseptic or diagnostic agent.

4. Ophthalmologic preparation according to claim 3, **characterized in that,** the active agent is hydrophobic, and it is contained in the nano-fibers in the form of micelles.

5. Ophthalmologic preparation according to claims 3 or 4, **characterized in that,** the content of the active agent is 0.01 to 50 wt.%, preferably 0.1 to 50 wt.%.

6. Ophthalmologic preparation according to any one of claims 1 to 5, **characterized in that**, the content of hyaluronic acid and/or derivative of hyaluronic acid or pharmaceutically acceptable salts thereof is in the range 5 to 90 wt.%, preferably 10 to 90 wt.%, more preferably 50 to 80 wt.%.

7. Ophthalmologic preparation according to claim 6, **characterized in that,** the mass ratio of hyaluronic acid or salt thereof and derivative of hyaluronic acid is 1/9 to 9/1, preferably 3/7 to 7/3.

8. Ophthalmologic preparation according to any one of the claims 1 to 7, **characterized in that,** the content of the synthetic polymer or the mixture thereof is in the range 10 to 95 wt.%, preferably 10 to 90 wt.%, more preferably 20 to 50 wt.%.

9. Ophthalmologic preparation according to the claim 8, **characterized in that,** the mass ratio of polyethylene oxide and polyvinyl alcohol in the mixture is in the range 19/1 to 3/17.

10. Ophthalmologic preparation according to any one of the claims 1 to 9, **characterized in that,** the nano-fibers have diameters in the range 50 to 1 000 nm, preferably 50 to 500 nm, more preferably 50 to 200 nm.

11. Ophthalmologic preparation according to any one of the claims 1 to 10, **characterized in that**, it is in the form of the nano-fibrous layer, the areal mass thereof being in the range 1 to 100 g/m^2, preferably in the range from 1 to 20 g/m^2, more preferably from 3 to 17 g/m^2.

12. Ophthalmologic preparation according to any one of the claims 1 to 11, **characterized in that,** it is equipped with a holder for manipulation during its application.

13. Ophthalmologic preparation according to any one of claims 1 to 12 for the use in treatment or prevention of ophthalmologic states, preferably ophthalmologic diseases and disorders selected from the group comprising glaucoma, syndrome of dry eye, macular degeneration, infection, inflammation or allergy.